Pulike Biological Engineering

Pulike Biological Engineering OCF Margin

The Operating Cash Flow Margin of Pulike Biological Engineering (603566.SS) as of Oct 17, 2026 is 32.70 %. In the previous year, Operating Cash Flow Margin was 25.78 % — a change of 26.82% (higher).

OCF Margin

32.70 %

YoY

26.82%

Last updated:

Operating Cash Flow Margin of Pulike Biological Engineering is 2025 32.70 % . Operating Cash Flow Margin of Pulike Biological Engineering was 2024 25.78 % . It decreases by 26.82% higher compared to the previous year.

The Pulike Biological Engineering OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
20.77 CNY
Jan 1, 2019
21.13 CNY
Jan 1, 2020
28.20 CNY
Jan 1, 2021
19.35 CNY
Jan 1, 2022
18.56 CNY
Jan 1, 2023
22.57 CNY
Jan 1, 2024
25.78 CNY
Jan 1, 2025
32.70 CNY
The Pulike Biological Engineering OCF Margin history
YEAROCF MarginYoY
32.70 %+26.82%
25.78 %+14.21%
22.57 %+21.60%
18.56 %-4.04%
19.35 %-31.39%
28.20 %+33.48%
21.13 %+1.73%
20.77 %-21.88%
26.58 %-38.74%
43.39 %+10.90%
39.13 %+23.10%
31.79 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pulike Biological Engineering Stock analysis

What does Pulike Biological Engineering do? Pulike Biological Engineering Inc, listed on the Shanghai Stock Exchange with ticker 603566.SS and ISIN CNE1000025N0, is a pharmaceutical company based in Luoyang, China. The company went public on May 18, 2015. It employs 1,718 people and operates within the healthcare sector, specifically in the pharmaceuticals industry. Pulike Biological Engineering focuses on the research, development, manufacturing, and sale of biological products for animals, chemical drugs, and Chinese veterinary drugs. The company's veterinary biological products include vaccines and antibodies, which are used for the prevention and control of infectious diseases in poultry and livestock. Its veterinary chemical medicines are primarily used for treating epidemic diseases affecting poultry and livestock. The company is headquartered in Luoyang, Henan, and its website is http://www.pulike.com.cn/. Pulike Biological Engineering Inc is engaged in the research, development, production, and distribution of veterinary biological products and chemical medicines. The firm's product portfolio targets the prevention and treatment of diseases in animals, with a focus on poultry and livestock health management. Pulike Biological Engineering is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pulike Biological Engineering stock

Operating Cash Flow Margin of Pulike Biological Engineering is 32.70 % in 2025.

Operating Cash Flow Margin of Pulike Biological Engineering changed from 25.78 % to 32.70 %, representing a 26.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Pulike Biological Engineering since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Pulike Biological Engineering with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Pulike Biological Engineering

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Pulike Biological Engineering